Fly News Breaks for October 19, 2018
NVS, ECYT
Oct 19, 2018 | 07:16 EDT
Wells Fargo analyst Jim Birchenough downgraded Endocyte (ECYT) to Market Perform from Outperform, citing the company's deal to be acquired by Novartis (NVS). He believes that the proposed acquisition price of $24 per share fairly reflects the potential value of the company's lead PSMA-targeted radionuclide therapeutic and sees Novartis as best positioned to realize that value based on its leadership in radionuclide therapeutics. Birchenough sees low odds of a competing offer and low risk of a material event to derail the acquisition, he added.
News For ECYT;NVS From the Last 2 Days
NVS
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.